New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:06 EDTMACKMerrimack announces positive clinical data for agent to treat breast cancer
Merrimack announced Phase I clinical trial results for MM-302, the company's agent for the treatment of advanced HER2 positive breast cancer. The findings demonstrated preliminary safety and tolerability.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
11:55 EDTMACKMerrimack pipeline progressing despite MM-111 discontinuation, says Cantor
Subscribe for More Information
11:49 EDTMACKMerrimack stops MM-111 development after DSMB recommendation
Subscribe for More Information
07:29 EDTMACKMerrimack reports Q4 EPS (9c), consensus (19c)
Reports Q4 revenue $33.91M, consensus $28.78M.
February 19, 2015
08:17 EDTMACKMerrimack initiates Phase 2 biomarker-selected clinical trial of MM-121
Merrimack Pharmaceuticals announced the initiation of a global, open-label, biomarker-selected, randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive, locally advanced or metastatic non-small cell lung cancer. As part of this trial, Merrimack expects to enroll approximately 120 heregulin positive patients that will be randomized to receive either MM-121 plus the investigator's choice of docetaxel or pemetrexed, or the investigator's choice of docetaxel or pemetrexed alone.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use